Hubei Hongyuan Pharmaceutical Technology Co Ltd. Stock Analysis 301246.SZ

Hubei Hongyuan Pharmaceutical Technology Co., Ltd. engages in the research, development, production, sales of organic chemical raw materials, pharmaceutical intermediates, APIs and pharmaceutical preparations. The company is headquartered in Huanggang, Hubei. The company went IPO on 2023-03-20. The firm is also engaged in the production of lithium hexafluorophosphate, one of the main materials for lithium battery electrolyte. The firm's main products are divided into organic chemical raw materials such as glyoxal in the ethylene glycol reaction chain, pharmaceutical intermediates such as glyoxylic acid, 2-methyl-5-nitroimidazole and other products, and raw materials such as metronidazole; Pharmaceutical intermediates guanine, diacetylguanine and other products in the reaction chain of methyl cyanoacetate and guanidine hydrochloride. The firm distributes its products in the domestic market and overseas markets.